血清抑制素A对急性呼吸窘迫综合征患者预后的评估价值
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

陕西省社会发展科技攻关项目(2016SF-075)


The prognostic value of serum inhibin A in patients with acute respiratory distress syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    探讨血清抑制素A对急性呼吸窘迫综合征(ARDS)患者预后的评估价值。方法 选取2017年6月~2020年9月延安大学附属医院收治的102名ARDS患者为观察对象,根据患者预后情况分为死亡组(48例)和存活组(54例),同时根据疾病严重程度分为轻度组(22例)、中度组(42例)和重度组(38例)。应用酶联免疫吸附法测定血清抑制素A及相关炎症指标水平。比较不同严重程度ARDS患者血清抑制素A水平差异,应用ROC曲线分析各指标对ARDS死亡的诊断价值,采用多因素Logistic逐步回归模型探讨ARDS发生死亡的相关因素。结果 与存活组比较,死亡组WBC、ALB、AST、GGT水平升高(P<0.05),而Hb、HCT、PLT、TBIL、DBIL、GLU、Ca、Cr、CHOL、HDL-C、LDL-C、TG水平比较差异无统计学意义(P>0.05)。与存活组比较,死亡组血清IL-4、TNF-α、hs-CRP水平和APACHE Ⅱ评分升高,差异均有统计学意义(P<0.05)。与存活组比较,死亡组血清抑制素A水平升高(P<0.05)。与ARDS轻度组比较,ARDS中度组和ARDS重度组血清抑制素A水平升高(P<0.05);随着ARDS病情逐渐严重,血清抑制素A水平逐渐升高(P<0.05)。血清抑制素A与IL-4、WBC、ALB、TNF-α、hs-CRP、APACHE Ⅱ评分呈正相关(P<0.05)。血清抑制素A诊断急性呼吸窘迫综合征患者发生死亡的AUC、灵敏度、特异度明显高于hs-CRP和APACHE Ⅱ评分(P<0.05)。多因素Logistics回归分析显示,高水平抑制素A、hs-CRP、APACHE Ⅱ评分为急性呼吸窘迫综合征患者发生死亡的危险因素(P<0.05)。结论 血清抑制素A评估急性呼吸窘迫综合征预后具有较高的灵敏度、特异度,其升高为急性呼吸窘迫综合征患者预后的危险因素

    Abstract:

    To investigate the prognostic value of serum inhibin A in patients with acute respiratory distress syndrome. Methods A total of 102 ARDS patients admitted to The Affiliated Hospital of Yan'an University from June 2017 to September 2020 were selected as the research objects. According to the prognosis of the patients. They were divided into death group (48 cases) and survival group (54 cases), and according to the severity of the disease, they were divided into mild group (22 cases), moderate group (42 cases) and severe group (38 cases). Enzyme linked immunosorbent assay (ELISA) was used to determine the levels of serum inhibit A and related inflammatory markers. The difference of serum inhibit A levels among each group was compared. The diagnostic value of each index in the death of ARDS was analyzed by ROC curve. The related factors of death of ARDS were discussed by multivariate logistic regression model. Results Compared with the survival group, the levels of WBC, ALB, AST and GGT increased in the death group of ARDS (P<0.05)), but there was no significant difference in the levels of Hb, HCT, PLT, TBIL, DBIL, Glu, CA, Cr, CHOL, HDL-C, LDL-C and TG (P>0.05). Compared with the survival group, the levels of IL-4, TNF-α, Hs-CRP and APACHE Ⅱ score in the death group increased, and the differences were statistically significant (P<0.05). Compared with the survival group, the serum inhibit A level in the death group was higher (P<0.05). Compared with mild ARDS group, the serum inhibit A level in moderate and severe ARDS groups was higher (P<0.05), and with the severity of ARDS, the serum inhibit A level gradually increased (P<0.05). Serum inhibit A was positively correlated with IL-4, WBC, ALB, TNF-α, Hs-CRP and APACHE Ⅱ score (P<0.05). The AUC, sensitivity and specificity of serum inhibit A in the diagnosis of death in patients with acute respiratory distress syndrome were 0.898 (95%CI: 0.848-0.955), 85.4% and 85.2%, respectively, which were significantly higher than those of hs-CRP and APACHE Ⅱ score (P<0.05). Multivariate logistic regression analysis showed that high level of inhibit A[ORand 95%CI: 4.595 (1.780-11.865)], hs-CRP [ORand 95%CI: 2.319 (1.497-3.589)], APACHE II score [OR and 95%CI:2.192 (1.367-3.516)] were the risk factors of death in patients with acute respiratory distress syndrome (P<0.05). Conclusion Serum inhibin A is positively correlated with the severity of acute respiratory distress syndrome. Serum inhibin A has high sensitivity and specificity in diagnosing the prognosis of acute respiratory distress syndrome. The increase of serum inhibin A is a prognostic risk factor for patients with acute respiratory distress syndrome.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-01-17
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司